scholarly journals Optimal Partitioning Method for Evaluating of Effect of Hemoglobin Oxygenation Levels of Vessel Endothelial Growth Factor

2018 ◽  
Vol 13 (2) ◽  
pp. 563-590
Author(s):  
O.V. Senko ◽  
M.S. Kodryan ◽  
A.V. Kuznetsova ◽  
L.L. Klimenko ◽  
A.I. Deev ◽  
...  
Keyword(s):  
Growth Factor ◽  
Multiple Testing ◽  
Permutation Test ◽  
Correlation Coefficients ◽  
Serum Levels ◽  
Joint Effect ◽  
Oxygenation Level ◽  
Hemoglobin Oxygenation ◽  
Paper Technique ◽  
Endothelial Growth Factor

The work is aimed to study relationship between vessel endothelial growth factor (VEGF) serum levels and hypoxia in patients with severe neurological disorders. Overviewed literature sources indicate activation of VEGF synthesis during hypoxia. But standard correlation analysis does not reveal a statistically significant association between VEGF levels and pulse oxymetry parameters objectively assessing oxygen supply. Due to a proposed in the paper technique it became possible to reveal valid relationship between VEGF levels and oxygenation. This relationship can be described as increase of correlation between VEGF and immunological complement C4 when oxygenation level is below a certain threshold. Developed method includes searching of such boundaries for oxymetry parameters that correlation coefficients between VEGF and some additional factor Z in formed group are maximally different. ranges. The original technique based on permutation test was used not only to asses validity of effects associated with each oxymetry parameter but also to evaluate joint effect by full group of such factors. Great number of variable from database were tested as additional factors. So additional correction of validity was made to take into account multiple testing.

scholarly journals Female sexual dysfunction in systemic sclerosis: The role of endothelial growth factor and endostatin

2018 ◽  
Vol 4 (1) ◽  
pp. 71-76 ◽  
Author(s):  
Antonietta Gigante ◽  
Luca Navarini ◽  
Domenico Margiotta ◽  
Biagio Barbano ◽  
Antonella Afeltra ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Blood Flow ◽  
Systemic Sclerosis ◽  
Growth Factor ◽  
Sexual Dysfunction ◽  
Resistive Index ◽  
Serum Levels ◽  
Vascular Endothelial ◽  
Healthy Controls ◽  
Endothelial Growth Factor

Introduction: Since female sexual dysfunction in systemic sclerosis women is multifactorial, we can assume that vascular damage may play a role in pathogenesis. The aim of the study was to evaluate the clitoral blood flow, by Echo color Doppler, and to correlate it whit serum levels of vascular endothelial growth factor and endostatin. Methods: A total of 15 systemic sclerosis women and 10 healthy controls matched for sex and age were enrolled in this study. Serum VEGF165 and endostatin levels were determined in systemic sclerosis patients by commercial enzyme-linked immunosorbent assay kit. Clitoral blood flow was measured by Doppler indices of clitoral artery: pulsatile index, resistive index, and systolic/diastolic ratio were measured. Sexual dysfunction was assessed by Female Sexual Function Index. Results: Vascular endothelial growth factor (pg/mL) and endostatin (ng/mL) median values were significantly higher in systemic sclerosis women than healthy controls. Resistive index and systolic/diastolic ratio median values were significantly higher in systemic sclerosis women than healthy controls. Negative correlation exists between serum levels of vascular endothelial growth factor and resistive index (r = −0.55, p < 0.05). Positive correlation was observed between serum levels of endostatin and resistive index (r = 0.70, p < 0.01) and systolic/diastolic ratio (r = 0.77, p < 0.01). Discussion: We can suppose that clitoral blood flow in systemic sclerosis women is reduced not only for macro- and microvascular damage but also for impaired angiogenesis.

scholarly journals Short Communication: Interaction of Nerve Growth Factor (NGF) and Vascular Endothelial Growth Factor (VEGF) in Healthy Individuals

2019 ◽  
Vol 2019 ◽  
pp. 1-5 ◽  
Author(s):  
Adrian Groh ◽  
Kirsten Jahn ◽  
Michael Gröschl ◽  
Thomas Hillemacher ◽  
Johannes Kornhuber ◽  
...  
Keyword(s):  
Growth Factor ◽  
Short Communication ◽  
Basic Research ◽  
Serum Levels ◽  
Psychiatric Diseases ◽  
Vascular Endothelial ◽  
Healthy Individuals ◽  
Communication Interaction ◽  
Endothelial Growth Factor ◽  
Vegf Level

NGF and VEGF are known to be involved in different psychiatric diseases. In order to verify hints from basic research that both neurotrophines interact with each other, serum levels of NGF and VEGF were measured in a cohort of 33 healthy individuals and correlated. NGF level was 126.30 pg/mL (±155.43), and VEGF level was 57.28 pg/mL (±44.48). Both factors were significantly correlated, confirming their interaction and legitimising the usage of their respective ratio (0.8 (±0.42)) as a less varying additional marker in prospective studies.

Vascular Endothelial Growth Factor (VEGF) Serum Levels during Cancer Immunotherapy with IL-2: Preliminary Considerations

1998 ◽  
Vol 13 (2) ◽  
pp. 98-101 ◽  
Author(s):  
P. Lissoni ◽  
L. Fumagalli ◽  
L. Giani ◽  
F. Rovelli ◽  
G Confalonieri ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Cancer Immunotherapy ◽  
Cancer Patients ◽  
Cell Cancer ◽  
Free Fraction ◽  
Serum Levels ◽  
Angiogenic Factor ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor

Neoangiogenesis has been proven to play a fundamental role in promoting cancer spread, and vascular endothelial growth factor (VEGF) is known to represent one of the most important angiogenic factors. The present study was planned to investigate changes in VEGF secretion in cancer patients undergoing immunotherapy with IL-2, with the aim of establishing whether VEGF variations play a role in mediating the IL-2-induced control of neoplastic diseases. The study involved 14 metastatic renal cell cancer patients treated with IL-2 immunotherapy (6 million IU/day subcutaneously for 6 days/week for 4 weeks). The clinical response consisted of partial response (PR) in 3, stable disease (SD) in 6 and progressive disease (PD) in the remaining 5 patients. VEGF serum levels were measured by an enzyme immunoassay designed to determine both bound and unbound VEGF. No significant changes in VEGF mean levels occurred during IL-2 therapy. Moreover, neither in patients with PR or SD nor in those with PD did the mean serum levels of VEGF change significantly in response to IL-2. This preliminary study seems to exclude that changes in the angiogenic factor VEGF may play a role in mediating the therapeutic efficacy of IL-2 cancer immunotherapy. However, since the method of measurement used in our study was designed to detect the total amount of VEGF, it cannot be excluded that changes in the free fraction of the molecule may occur during IL-2 cancer immunotherapy.

Sign in / Sign up

Export Citation Format

Share Document